BRCA and lynch syndrome-associated ovarian cancers behave differently
نویسندگان
چکیده
منابع مشابه
BRCA and lynch syndrome-associated ovarian cancers behave differently
We are delighted to have the opportunity to respond to the letter by Gilks et al. (Gilks et al., 2017). They argue first that historical pathological entities do not map seamlessly to modern day diagnostic categories, which are not only based on expert review by specialist gynecological pathologists but are also increasingly supported by immunohistochemistry (IHC). Second, that the misclassific...
متن کاملBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pathways, such as prostate, lung, endometrial, and pancreatic cancers. Several PARPi are currently i...
متن کاملEndoscopically Diagnosed Gastric Cancers: Looking Alike, but Behave Differently
cancer remains the second leading cause of cancer mortality in the world, although the overall incidence is gradually declining. 1 Gastric cancers can be largely subdivided into early and advanced lesions in nature or intestinal and diffuse type in pathology. Early gastric cancer (EGC) is defined as a cancer that does not invade beyond the submucosa regardless of lymph node involvement, based o...
متن کاملMale breast cancers behave differently in elderly patients.
OBJECTIVE The aim of this study was to evaluate tumor characteristics, management and survival in elderly male breast cancer patients in comparison with younger men. METHODS We reviewed medical records of 99 male breast cancer patients between 1972 and 2011. The median age of the patients was 64.5 years. Patient characteristics including clinicopathologic factors, treatment modalities, surviv...
متن کاملProstate cancer screening in BRCA and Lynch syndrome mutation carriers.
Prostate cancer (PrCa) remains a major public health burden worldwide. Screening programs have been established using the most efficient biomarker to date-prostate-specific antigen (PSA)-with the goal of earlier detection of this disease, which is thought to translate to a reduction in PrCa mortality. However, these screening programs have proved to be controversial following the publication of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Gynecologic Oncology Reports
سال: 2017
ISSN: 2352-5789
DOI: 10.1016/j.gore.2017.11.007